Efficacy and safety of pasireotide LAR or everolimus alone, or in combination in patients with advanced carcinoids (NET) of the lung/thymus: results from the randomized, phase 2 LUNA study.
dc.contributor.author | Ferolla, P | |
dc.contributor.author | Brizzi, M | |
dc.contributor.author | Meyer, T | |
dc.contributor.author | Mansoor, Was | |
dc.contributor.author | Mazieres, J | |
dc.contributor.author | Cao, C | |
dc.contributor.author | Lena, H | |
dc.contributor.author | Berruti, A | |
dc.contributor.author | Damiano, V | |
dc.contributor.author | Buikhuisen, W | |
dc.contributor.author | Stankovic, M | |
dc.contributor.author | Singh, N | |
dc.contributor.author | Chiodini, E | |
dc.contributor.author | Gislimberti, G | |
dc.contributor.author | Oberg, K | |
dc.contributor.author | Baudin, E | |
dc.date.accessioned | 2017-05-02T19:48:16Z | |
dc.date.available | 2017-05-02T19:48:16Z | |
dc.date.issued | 2016-10-01 | |
dc.identifier.citation | Efficacy and safety of pasireotide LAR or everolimus alone, or in combination in patients with advanced carcinoids (NET) of the lung/thymus: results from the randomized, phase 2 LUNA study. 2016, 27(suppl 6):4160 Annals of Oncology | en |
dc.identifier.issn | 0923-7534 | |
dc.identifier.issn | 1569-8041 | |
dc.identifier.doi | 10.1093/annonc/mdw369.01 | |
dc.identifier.uri | http://hdl.handle.net/10541/620308 | |
dc.language.iso | en | en |
dc.relation.url | https://academic.oup.com/annonc/article/2799155/Efficacy | en |
dc.rights | Archived with thanks to Annals of Oncology | en |
dc.title | Efficacy and safety of pasireotide LAR or everolimus alone, or in combination in patients with advanced carcinoids (NET) of the lung/thymus: results from the randomized, phase 2 LUNA study. | en |
dc.type | Meetings and Proceedings | en |
dc.contributor.department | Dept. of Medical Oncology, Multidisciplinary NET Group, Umbria Regional Cancer Network and University of Perugia, Perugia | en |
dc.identifier.journal | Annals of Oncology | en |